Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of localized breast cancer~  * Stage I or II (T1-3, N0-2, M0)~* Planned adjuvant chemotherapy (after surgery) of at least 6 months in duration~* Hormone receptor status:~  * Estrogen receptor and progesterone receptor status known~PATIENT CHARACTERISTICS:~Age~* 18 to 50~Sex~* Female~Menopausal status~* Premenopausal or perimenopausal~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Creatinine less than 2 mg/dL~Other~* No T score of less than 2.0 on bone mineral density (BMD)~* No fragility fracture~* No lumbar spine anatomy that would preclude accurate BMD measurement of a minimum of 3 lumbar vertebrae~* Not pregnant~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~Other~* At least 1 month since prior calcitonin~* At least 12 months since prior bisphosphonates given for more than 1 month duration~* No concurrent fluoride therapy (10 mg/day or more)~* No concurrent enrollment in another experimental drug study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).